14-month LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma showed 50% complete response and 71% overall response rate.
14-month follow-up data from the LINKER-MM1 trial of linvoseltamab showed 50% of patients with relapsed/refractory multiple myeloma achieved a complete response or better, and 71% had an overall response rate. These results were presented at the European Hematology Association Congress 2024 and published in the Journal of Clinical Oncology.
June 16, 2024
4 Articles